Trials / Completed
CompletedNCT01965613
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
Detailed description
XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Xilonix | IV |
Timeline
- Start date
- 2014-01-31
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
- First posted
- 2013-10-18
- Last updated
- 2025-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01965613. Inclusion in this directory is not an endorsement.